A5082877006- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Meningioma and schwannoma management
- Tryptophan and brain disorders
- Intensive Care Unit Cognitive Disorders
- Frailty in Older Adults
- Functional Brain Connectivity Studies
- Essential Oils and Antimicrobial Activity
- Vascular Malformations Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Long-Term Effects of COVID-19
- Radiomics and Machine Learning in Medical Imaging
- Advanced Chemical Sensor Technologies
- Olfactory and Sensory Function Studies
- Nutrition and Health in Aging
- Neuroblastoma Research and Treatments
- Medical Imaging Techniques and Applications
University of Padua
2021-2025
Purpose To evaluate if reduced muscle mass, assessed with Computed Tomography (CT), is a predictor of intensive care unit (ICU) hospitalization in COVID-19 patients. Methods In this Institution Review Board approved study, we retrospectively evaluated patients treated our tertiary center from March to November 2020 who underwent an unenhanced chest CT scan within three weeks hospitalization.We recorded the mean Hounsfield Unit (Hu) value right paravertebral at level 12 th thoracic vertebra,...
Abstract Purpose Bevacizumab is an anti-angiogenetic treatment that can be used in patients with recurrent glioblastoma, but there are limited and controversial data on the optimal dose schedule, associated toxicities survival benefits of different doses. Methods A retrospective analysis IDH wt glioblastoma treated bevacizumab at Veneto Institute Oncology was performed. Patients received 2 schedules (5 mg/kg or 10 q2w), as monotherapy combination chemotherapy. Results 81 were analyzed, 33 5...
Transient or persistent hypo-anosmia is common in SARS‑CoV‑2 infection but olfactory pathway late-term morphometric changes are still under investigation. We evaluated late bulb (OB) imaging and their correlates with the function otherwise neurologically asymptomatic COVID-19 patients. Eighty-three subjects (mean-age 43 ± 14 yr; 54 females; time-interval infection/MRI: 129±68 d) were affected by to mild 2020 25 healthy controls 40 13 9 females) underwent 3T-MRI evaluation through anamnestic...
Data on the use of targeted therapies in glioma are still limited and identification useful targetable mutations is under investigation. Among all relevant alterations identified through next generation sequencing (NGS) tests, ROS1 can rarely be found gliomas, most common them GOPC::ROS1 fusion. Targeted therapies, such as entrectinib, available for alterations. Hereby, case a patient affected by fused glioblastoma treated with entrectinib presented; this achieved complete prolonged response...